• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 3. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 4. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 5. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459

Introduction to N-(Quinolin-8-yl)acetamide (CAS No. 33757-42-5)

N-(Quinolin-8-yl)acetamide, identified by the Chemical Abstracts Service Number (CAS No.) 33757-42-5, is a significant compound in the field of pharmaceutical chemistry and bioorganic synthesis. This heterocyclic amide derivative has garnered considerable attention due to its structural uniqueness and potential biological activities. The presence of a quinoline moiety in its molecular framework imparts distinctive electronic and steric properties, making it a valuable scaffold for the development of novel therapeutic agents.

The quinoline core is a well-documented pharmacophore in medicinal chemistry, with a rich history of applications in treating various diseases, including malaria and bacterial infections. The acetylamide functional group further enhances the compound's versatility, allowing for modifications that can fine-tune its pharmacokinetic and pharmacodynamic profiles. This combination of structural elements has positioned N-(Quinolin-8-yl)acetamide as a promising candidate for further investigation in drug discovery.

In recent years, advancements in synthetic methodologies have enabled the efficient preparation of complex quinoline derivatives. The synthesis of N-(Quinolin-8-yl)acetamide typically involves condensation reactions between 8-hydroxyquinoline and acetic anhydride or acetyl chloride, followed by purification steps to isolate the desired product. These synthetic routes have been optimized to ensure high yields and purity, facilitating its use in downstream applications.

The biological significance of N-(Quinolin-8-yl)acetamide has been explored in several preclinical studies. Its quinoline moiety interacts with various biological targets, including enzymes and receptors, which are implicated in metabolic pathways and signal transduction processes. Preliminary research suggests that this compound may exhibit inhibitory effects on certain enzymes, making it a potential lead for the development of drugs targeting inflammatory and infectious diseases.

One of the most intriguing aspects of N-(Quinolin-8-yl)acetamide is its potential role in modulating immune responses. Quinoline derivatives have been known to interact with immune cells and cytokine pathways, suggesting that this compound could have immunomodulatory properties. Further studies are needed to elucidate the exact mechanisms by which it exerts these effects, but the preliminary findings are promising.

The pharmacokinetic properties of N-(Quinolin-8-yl)acetamide are also under investigation. Its molecular structure suggests that it may have good oral bioavailability and moderate metabolic stability, which are critical factors for any drug candidate. However, detailed pharmacokinetic studies are necessary to confirm these predictions and to identify any potential liabilities that need to be addressed during drug development.

In conclusion, N-(Quinolin-8-yl)acetamide (CAS No. 33757-42-5) is a structurally interesting compound with significant potential in pharmaceutical research. Its unique combination of a quinoline core and an acetylamide group makes it a versatile scaffold for drug discovery. While further research is needed to fully understand its biological activities and pharmacokinetic properties, the current evidence suggests that it could be a valuable addition to the arsenal of compounds being explored for therapeutic applications.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)